CVC retains majority stake in Syntegon as Apollo joins as strategic minority investor to support next phase of global growth

CVC retains majority stake in Syntegon as Apollo joins as strategic minority investor to support next phase of global growth

(IN BRIEF) CVC Capital Partners has agreed to sell a 37% minority stake in Syntegon to Apollo-managed funds while retaining majority ownership, marking the start of a new growth phase for the company. Since CVC’s investment, Syntegon has achieved strong financial performance, including record revenues of €1.75 billion and significantly increased profitability, establishing itself as a global technology leader in the pharmaceutical, biotech, and food industries. Apollo’s involvement is expected to bring additional expertise, particularly to support expansion in the North American market. With a large installed base of systems, a strong innovation pipeline, and a history of strategic acquisitions, Syntegon is positioned to continue its growth trajectory. The company will maintain its current leadership and operational structure as it focuses on scaling its global presence and unlocking further service potential.

(PRESS RELEASE) LUXEMBOURG, 23-Mar-2026 — /EuropaWire/ — CVC Capital Partners has announced that funds managed by Apollo will acquire a 37% minority stake in Syntegon, while CVC will retain its majority ownership with a 63% shareholding, reaffirming its long-term commitment to the company’s continued growth and strategic direction.

The transaction marks the beginning of a new phase in Syntegon’s development, following a period of significant transformation under CVC’s ownership. It reflects CVC’s approach of fostering sustainable growth through long-term partnerships and the selective inclusion of strategic co-investors. Apollo’s involvement is expected to contribute additional expertise, particularly in accelerating Syntegon’s expansion in the North American market.

Syntegon has experienced substantial growth since CVC’s investment, achieving record revenues of €1.75 billion in 2025 and significantly increasing profitability, with operating profit quadrupling over the period. The company has strengthened its position as a leading provider of advanced technology solutions for the pharmaceutical, biotechnology, and food industries, supported by a global installed base of approximately 72,000 systems.

Marc Strobel, Chairman of Syntegon’s Supervisory Board and Partner at CVC, highlighted the strong performance delivered by the management team under CEO Torsten Türling, noting that the company has established itself as a leader in highly regulated and technologically demanding markets. He emphasized that introducing a minority shareholder will support further global expansion and unlock additional growth opportunities.

Can Toygar, also a member of the Supervisory Board and Partner at CVC, pointed to Syntegon’s transformation as an example of CVC’s long-term investment strategy. He noted that through targeted acquisitions and strategic investments, the company has evolved into a global market leader, positioning it well for continued expansion with Apollo as a new partner.

Torsten Türling, CEO of Syntegon, described the agreement as a key milestone for the company, underlining the continuity of its partnership with CVC while welcoming Apollo’s contribution to future growth. He noted that Syntegon’s current position reflects strong performance across its global operations, with ongoing innovation, enhanced operational efficiency, and a broad portfolio of advanced technologies.

Apollo also expressed confidence in Syntegon’s trajectory, with Jeremy Honeth, Partner at Apollo, highlighting the company’s role as a technology leader within critical pharmaceutical, biotech, and food supply chains. He emphasized the opportunity to support continued growth, particularly in the United States.

Syntegon’s strong performance is underpinned by its integrated solutions across the production lifecycle, a portfolio of around 2,000 patents and patent applications, and innovations such as SynTiso, a high-speed gloveless filling line for liquid pharmaceuticals. The company’s transformation has been driven by a combination of organic growth, operational improvements, new facility development, and strategic acquisitions, including Telstar in 2024 and a majority stake in Klenzaids in 2023.

Looking ahead, Syntegon plans to focus on expanding its presence in resilient, high-growth markets, with particular emphasis on North America. The company also aims to further leverage its extensive installed base by expanding its service offerings.

The transaction remains subject to customary regulatory approvals, with financial terms not disclosed. Syntegon will continue to operate under its existing management team from its headquarters in Stuttgart, maintaining its focus on sustained, profitable growth.

Media Contact:

Patrick Humphris
Managing Director, Head of Corporate Affairs
CVC
Tel: +44 204 576 9526
phumphris@cvc.com

SOURCE: CVC Capital Partners